Virologic Outcomes of Common First-Line Antiretroviral Regimens Among Adults with HIV - China, 2021-2023.

Authors

Hanlu Jia, Yan Zhao, Yuan Guan, Jiang Liu, Yunxia Geng, Xiumin Gan, Yufen Liu

Published in

China CDC weekly. Volume 8. Issue 27. Pages 835-840. Jul 03, 2026.

Abstract

Antiretroviral therapy (ART) is the cornerstone of HIV care. In China, efavirenz-based regimens have long been widely used as first-line treatment, while integrase strand transfer inhibitor (INSTI)-based regimens are increasingly available. However, nationwide evidence on virologic outcomes across common first-line regimens remains limited.
This nationwide cohort study found higher viral suppression with EFV 400 mg-based regimens compared with EFV 600 mg- and LPV/r-based regimens, while INSTI-based regimens showed the highest suppression overall.
Findings support expanded use of INSTI-based regimens and consideration of EFV 400 mg-based regimens during ongoing optimization of first-line ART in China.

PMID:
42434703
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.